Video
Dr. Elhassadi on 10-Year Single-Center Experience With TP53 Status in MCL
Author(s):
Ezzat Elhassadi, MD, consultant hematologist, Hematology Services, University Hospital Waterford, discusses a 10-year single-center experience with TP53 status in mantle cell lymphoma (MCL).
Ezzat Elhassadi, MD, consultant hematologist, Hematology Services, University Hospital Waterford, discusses a 10-year single-center experience with TP53 status in mantle cell lymphoma (MCL).
At the 2019, ASCO Annual Meeting, Elhassadi presented the 10-year single-center experience data with TP53 status in patients with MCL. Twenty-nine previously treated patients were recruited to the study where investigators collected 32 patient samples. Patients received a variety of combinations. Over the study period, which ranged from 2006 to 2016, 11 deaths were reported. Of the 11 deaths, 6 were non-lymphoma—related and 5 were lymphoma-related as a result of disease progression.
These data fell in line with published literature in the field, says Elhassadi. Further analysis from p53 mutation screening in the lymphoma-related cohort revealed that as many as 80% of patients harbored a p53 mutation, which is a known poor prognostic indicator in MCL.
